Council of Scientific and Industrial Research

Other

Zandu Pharmaceutical Works Ltd.

Kasturi Lal Bedi

Naresh Kumar Satti

Krishan Avtar Suri

Om Parkash Suri

Ghulam Nabi Qazi

Rakesh Kamal Johri

Bishan Datt Gupta

Subhash Chander Sharma

Anamika Khajuria

Bal Krishan Kapahi

Ashok Kumar Tikoo

Manoj Kumar Tikoo

Sukhdev Swami Handa

Bal Krishan Chandan

Bupinder Singh Jaggi

Vikram Bhardwaj

Vishwa Nath Gupta

Ravi Kant Khajuria

Om Prakash Suri

Anpurna Kaul

Girish G Parikh

Raman Krishnamurthy

Prabhakar Kulhar

Ulhas Salunkhe

Surjit Singh

Sheikh Tasaduq Abdullah

Inshad Ali Khan

Vijeshwar Verma

Dilip Manikrao Mondhe

Gulam Nabi Qazi

Randhir S Kapil

Kuldeep Singh

Devinder Kumar Gupta

Gurdarshan Singh

Anil Prabhakar

Neelam Sharma

Satinder Mohan Jain

Musarat Amina

Usha Zutshi

Santosh K Dhar

Naveen Kapoor

Gurbax Singh

Rajinder Singh

Ashok K Tickoo

Manoj K Tickoo

Jawahar L Kaul

Ram K Zutshi

Swadesh Malhotra

Gurcharan S Pahwa

Ramesh K Johri

Surjeet Singh

Kuldip Kumar Gupta

Uma Kaul

Vijay Kumar Sharma

Shankar Lal

Sheikh Tasaduq Absullah

The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising:

[object Object]

The present invention provides a method for treating and/or preventing hepatic disease conditions in a subject mammals including human beings, said method comprising the steps of administering to the mammal an effective dosage of composition comprising 2'-p-Hydroxy benzoyl mussaenosidic acid from plantoptionally as individual or in combination with one or more pharmaceutically additives.

Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid

The present invention relates to the use of bioenhancers to decrease the resistance of microbial strains to anti-infective such an antibiotics and antifungals by potentiating the activities of anti-infective. This may be useful to reduce resistance in bacteria and yeast to aid in the treatment of certain infections and disease and to lower the concentration of antiinfectives necessary to inhibit the growth of microbial strains.

Use of herbal agents for potentiation of bioefficacy of anti infectives

The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract fromand optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.

A process of isolation of pure Acteoside of high hepatoprotection from plant, said process comprising steps of drying aerial parts of the plant, grounding the dried parts into powder, percolating the powder with water or ethanol for 3-4 times to obtain an extract, filtering the extract for clearing of suspended particles to obtain supernatant, drying the supernatant at about 45 to 55&#xb0; C. to obtain a residue, fractionating the residue with chloroform, ethyl acetate, and butanol successively, subjecting butanol fraction to adsorption chromatography of SiOafter adding methanol to the fraction, charging the adsorbed fraction to glass column, eluting the column with solvents of increasing polarity of methanol:chloroform to obtain further fractions and repeating the process one more time, subjecting the fractions to column chromatography to obtain fractions, concentrating the fractions under reduced pressure to obtain acteoside as residue; and a method of effectively hepatoprotecting a subject using pure Acteoside from plant, said method comprising steps of administering appropriate low-dose of the acteoside to the subject.

Hepatoprotective agent of plant origin and a process thereof

The present invention relates to a process for the isolation of a novel oligospirostanoside structurally constructed as 3-0-&lsqb;&agr;-L-rhamnopyranosyl-(1&rarr;2)-&agr;-L-rhamnopyranosyl-(1&rarr;4)-0-&bgr;-D-glucopyranosyl&rsqb;-25(S)-5&bgr; spirostan-3&bgr;-ol isolated from and biologically evaluated as a potent immunomodulatory agent.

Process for the isolation of novel oligospirostanoside

The present invention relates to a novel oligospirostanoside having the structure 3-0-&lsqb;&agr;-L-rhamnopyranosyl-(1&rarr;2)-&agr;-L-rhamnopyranosyl-(1&rarr;4)-0-&bgr;-D-glucopyranosyl&rsqb;-25(S)-5&bgr;-spirostan-3&bgr;-ol isolated from and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.

Oligospirostanoside, pharmaceutical composition containing novel oligospirostanoside and method for immunomodulation using said oligospirostanoside

A new pharmaceutical composition for the treatment of tuberculosis and leprosy, said composition comprising piperine in combination with known antituberculosis or antileprosy drugs or the mixtures thereof.

Process for preparation of pharmaceutical composition with enhanced

Growing community of inventors

Jammu, India

Kasturi Lal Bedi